Johnson & Johnson (NYSE: JNJ) is a well-established company known for its diverse range of products in the healthcare sector, including pharmaceuticals, medical devices, and consumer health products. On October 10, 2025, Shagun Singh from RBC Capital set a new price target for JNJ at $209. At the time, the stock was trading at $191.30, suggesting a potential increase of approximately 9.26%.
The potential acquisition of Protagonist Therapeutics, as reported by the Wall Street Journal, underscores Johnson & Johnson's strategic focus on expanding its pharmaceutical portfolio. This move aligns with the company's ongoing efforts to strengthen its position in the healthcare industry. The acquisition talks are still in the negotiation phase, indicating that Johnson & Johnson is actively seeking growth opportunities.
Johnson & Johnson is set to release its third-quarter earnings results on October 14. Analysts expect the company to report earnings of $2.76 per share, up from $2.42 per share in the same period last year. The anticipated quarterly revenue is $23.76 billion, an increase from $22.47 billion a year ago. These figures reflect the company's strong financial performance and growth trajectory.
In a significant development, the FDA has approved Johnson & Johnson's Simponi (golimumab) for children with moderately to severely active ulcerative colitis. This approval has positively impacted the stock, with shares rising by 0.7% to close at $191.08. The approval highlights Johnson & Johnson's commitment to expanding its product offerings and addressing unmet medical needs.
Currently, JNJ is trading at $191.29, with a slight increase of 0.21, reflecting a percentage change of 0.11%. The stock has fluctuated between a low of $190.31 and a high of $192.06 today. Over the past year, JNJ has reached a high of $192.1 and a low of $140.68. The company's market capitalization is approximately $460.69 billion, with a trading volume of 3,133,058 shares.
